CMC Readiness
CMC (Chemistry, Manufacturing and Controls) readiness is a major hurdle during drug discovery and development. Sufficient, compliant data and documentation regarding the manufacturing process, product stability, and quality controls of a drug are required for regulatory approval. When operations rely on disconnected tracking systems, teams can struggle with version control, data retrieval, and demonstration of end-to-end traceability1. The goal of CMC readiness is to develop and scale manufacturing processes, formulations, and analytical methods. To do this, organizations must establish integrated, compliant systems that ensure consistent data capture, cross-functional alignment, and clear traceability across the drug development lifecycle, enabling informed decision-making, efficient scale-up, and regulatory-ready documentation at every stage.
To achieve this, organizations can turn to Leadscope Model Applier™, Centrus®, and Logbook™ for more reliable laboratory operations, faster turnover times, and fewer traceability gaps when assembling CMC packages:
- Leadscope Model Applier™ complies with ICH guidelines and is essential for impurity qualification, helping minimize expensive synthesis and testing efforts while safeguarding patient safety through clear, well-justified assessments.
- Centrus® enables researchers to address and understand potential safety concerns that are applicable beyond target identification and lead optimization, as drug discovery moves into CMC readiness.
- Logbook™ supports consistent documentation practices and GLP-compliant audit trails, simplifying CMC audit preparation and submissions.
These solutions provide a compliant foundation that helps organizations achieve CMC readiness with greater confidence, efficiency, and regulatory success.
In the final stage of the molecule’s journey, teams must compile an IND package that is structured, complete, and fully SEND‑compliant. Our next post explores how Instem supports this critical milestone.
- Ahluwalia K, Abernathy MJ, Beierle J, et al. The Future of CMC Regulatory Submissions: Streamlining Activities Using Structured Content and Data Management. J Pharm Sci. 2022;111(5):1232-1244. doi:10.1016/j.xphs.2021.09.046 ↩︎
